Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Bile Acid Derivative Trims Fat from Double Chin

By BiotechDaily International staff writers
Posted on 14 Mar 2013
An injectable drug may help patients get rid of excess submental fat (SMF) without the need for surgery, according to a new study.

Under development by Bayer Healthcare (Munich, Germany) and Kythera Biopharmaceuticals (Calabasas, CA, USA), the investigational agent ATX-101 is a synthetically-derived deoxycholic acid that prompts adipocytolysis, the permanent destruction of the fat cell. In an interim analysis of ongoing phase III trials, which enrolled 2,500 participants, in which 1,500 have been given the drug and 1,000 have received placebo, the participants reported 87% satisfaction with the results.

To assess long-term safety and efficacy, the phase IIIb study conducted at 21 sites in the US over 12 months enrolled 165 patients with moderate SMF who reported being dissatisfied with the appearance of their face and chin; 78% were female and mean age was 47. All patients had a history of stable body weight and no prior interventions to treat their double chin. All received 2 mg/cm2 of the drug by subcutaneous microinjections with a 30-gauge needle directly into preplatysmal SMF for up to six treatment sessions at 28-day intervals.

The results of the interim analysis at week 32 showed that 86.8% of patients achieved greater than a one-point improvement on the clinician-reported SMF rating scale from baseline through 12 weeks after the last treatment. Patients also reported subjective improvement, with 83% having achieved at least a one-point improvement in self-reported SMF rating scores. The treatment also received high marks for other patient-reported outcomes, including facial appearance, chin and neck definition, and unchanged or improved skin laxity. The results of the study were presented at the American Academy of Dermatology annual meeting, held during March 2013 in Miami Beach (FL, USA).

“Most patients reported feeling less self-conscious and younger, and many patients said they looked like they had lost weight even though their body mass index remained the same,” said study presenter Susan Weinkle, MD, a dermatologist in private practice in Bradenton (FL, USA). “ATX-101 appears to be well tolerated and effective at reducing submental fat, and may very well provide, in the future, an approach to submental fat for our patients who are so unhappy with this part of their body.”

Deoxycholic acid is one of the secondary bile acids secreted by the liver. It is a byproduct derived from the metabolization of chenodeoxycholic acid by intestinal bacteria. In the human body deoxycholic acid is used in the emulsification of fats for the absorption in the intestine. It has, in some countries (including Switzerland) been licensed as an emulsifier in the food industry.

Related Links:

Bayer Healthcare
Kythera Biopharmaceuticals



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.